Resumen: Incyte anuncia que logró la aceptación de más de 20 resúmenes para su presentación en el Congreso 2026 de la European Hematology Association (EHA)
Wednesday, May 13, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: Incyte has announced the acceptance of over 20 abstracts for presentation at the 2026 European Hematology Association Congress. This indicates the company's ongoing commitment to advancing research in hematology. The details of the abstracts and their implications for the field will be highlighted during the congress.
Price reaction · baseline $99.13 (2026-05-12 close) · hit after-hours · clean, no other INCY news in the window
day 0 close
-0.3%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+44%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
INCB013739
Phase 2 · Type 2 Diabetes
Full Press Release Details
WILMINGTON, Delaware--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) anunció hoy que se presentarán datos de programas clave en sus franquicias de hematología y oncología en el Congreso 2026 de la European Hematology Association (EHA), que se llevará a cabo del 11 al 14 de junio en Estocolmo (Suecia).
El comunicado en el idioma original es la versión oficial y autorizada del mismo. Esta traducción es solamente un medio de ayuda y deberá ser comparada con el texto en idioma original, que es la única versión del texto que tendrá validez legal.
Frequently Asked Questions
How many abstracts did Incyte have accepted?
Incyte had over 20 abstracts accepted for the 2026 EHA Congress.
What is the significance of the accepted abstracts?
The accepted abstracts highlight Incyte's commitment to advancing hematology research.